MIRA
INFORM REPORT
|
Report Date : |
27.12.2013 |
IDENTIFICATION DETAILS
|
Name : |
SHANDONG RUIYING PIONEER PHARMACEUTICAL CO.,
LTD. |
|
|
|
|
Registered Office : |
NO. |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
30.11.2012 |
|
|
|
|
Date of Incorporation : |
22.03.2010 |
|
|
|
|
Com. Reg. No.: |
371700200010596 |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Subject is engaged in manufacturing and selling pharmaceutical
products |
|
|
|
|
No. of Employees : |
1,217 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March, 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
|
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Since the late 1970s
|
Source
: CIA |
Company name & address
SHANDONG RUIYING PIONEER PHARMACEUTICAL CO., LTD.
NO.
TEL: 86
(0) 530-5850184/5854766
FAX: 86 (0) 530-5850707
EXECUTIVE SUMMARY
INCORPORATION DATE : MAR. 22, 2010
REGISTRATION NO. : 371700200010596
REGISTERED LEGAL FORM : LIMITED LIABILITY
COMPANY
CHIEF EXECUTIVE :
MR. PENG JIXIAN (CHAIRMAN)
STAFF STRENGTH :
1,217
REGISTERED CAPITAL : CNY 325,000,000
BUSINESS LINE :
MANUFACTURING AND TRADING
TURNOVER :
CNY 416,669,000 (JAN. 1 TO nov. 30, 2012)
EQUITIES :
CNY 228,568,000 (AS OF nov. 30, 2012)
PAYMENT :
average
MARKET CONDITION : competitive
FINANCIAL CONDITION : fair
OPERATIONAL TREND : fairly STEADY
GENERAL REPUTATION : average
EXCHANGE RATE : CNY 6.0717= USD 1
Adopted
abbreviations:
ANS - amount not stated NS
- not stated SC - subject company (the
company inquired by you)
NA - not available CNY
- China Yuan Ren Min Bi
Note: the heading address is formerly known as the (
SC was registered as a Limited Liability Company at local Administration
for Industry & Commerce (AIC - The official body of issuing and renewing
business license) on Mar. 22, 2010.
Company Status: Limited Liability
Company This
form of business in PR China is defined as a legal person. No more than
fifty shareholders contribute its registered capital jointly. Shareholders
bear limited liability to the extent of shareholding, and the co. is liable
for its debts only to extent of its total assets. The characteristics of
this form of co. are as follows: Upon
the establishment of the co., an investment certificate is issued to the
each of shareholders. The
board of directors is comprised of three to thirteen members. The
minimum registered capital for a co. is CNY 30,000. Shareholders
may take their capital contributions in cash or by means of tangible assets
or intangible assets such as industrial property and non-patented
technology. Cash
contributed by all shareholders must account for at least 30% of the
registered capital. Existing
shareholders have pre-exemption right to purchase shares of the co. offered
for sale by the other shareholders and to subscribe for the newly increased
registered capital of the co.
SC’s registered business scope includes manufacturing and selling
sterile bulk drugs, pharmaceutical raw materials s, freeze-dried powder (anticancer);
manufacturing and selling dioxygen piperazine, dioxygen piperazine carbonyl
chloride, EPCP the HO-EPCP, cefoperazone crude, cefamandole ester crude,
cefpiramide crude product, 6 - methyl-4-hydroxy -3 pyridinecarboxylic acid
(A-4), 6 - methyl-4-hydroxy-smoke amide-p-hydroxyphenyl acetic acid (A-6),
trimethyl chlorosilane, 7-the ATCA, cephalosporin C, 7-ACA, amino acid oxidase,
aminoacylase, and GL-7-ACA acylase.
SC is mainly engaged in manufacturing and selling pharmaceutical
products.
Mr. Peng Jixian is the legal representative, chairman and general
manager of SC at present.
SC is known to have approx. 1,217 employees at present.
SC is currently operating at the above stated address, and this address
houses its operating office and factory in the industrial zone of Heze. The
detailed premise information is unknown.
http://www.ruiying.cn/
The design is professional and the content is well organized. At present it is
in Chinese and English versions.
Email: hj8136@163.com
; service@rychem.com
According to SC’s website, SC was originally known as Heze Ruiying Pharmaceutical
Group Co., Ltd.
Changes of its
registered information are as follows:
|
Date of change |
Item |
Before the change |
After the change |
|
Unknown |
Shareholder |
Shanghai Xinya Pharmaceutical Co., Ltd. 42.00% Peng Jixian 35% Shang Zhongdong 12% Zheng Quanhong 11% |
Present one |
For the past two years there is no record of litigation.
MAIN SHAREHOLDERS:
Name Amount
(CNY) % of Shareholding
Shandong Heyuan Chemical Co., Ltd. (literal
translation) 136,500,000 42.00
Peng Jixian 113,743,900 35.00
Shang Zhongdong 39,000,000 12.00
Zheng Quanhong 35,756,100
11.00
Shandong Heyuan Chemical Co., Ltd. (literal translation)
Legal representative: Ge Xinfang
Registration No.: 371721228000779
Incorporation date: Dec. 20, 2000
Registered capital: CNY 70,032,500
Legal representative,
Chairman and General Manager:
Mr. Peng Jixian is currently responsible for the overall management of
SC.
Working
Experience(s):
At present working
in SC as legal reprehensive, chairman and general manager
Directors:
Zheng Quanhong
Shang Zhongdong
Supervisor:
Pang Qingwen
SC is mainly engaged in manufacturing and selling pharmaceutical
products.
SC’s products mainly include: pharmaceutical intermediates, aseptic raw drugs,
biological pharmacy, anti-neoplastic drugs and pharmaceutical preparations
SC sources its materials 90% from domestic market, and 10% from the
overseas market, mainly European countries. SC sells 70% of its products in
domestic market, and 30% to the overseas market, mainly
The buying terms of SC include Check, T/T, L/C and Credit of 30-60 days.
The payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.
Note: SC’s
management declined to release its major clients and suppliers.
SC is not known to have any subsidiary at present.
Overall payment appraisal: ( )
Excellent ( ) Good
(X) Average ( ) Fair
( ) Poor (
) Not yet determined The appraisal serves as a reference to reveal SC's
payments habits and ability to pay. It
is based on the 3 weighed factors: Trade
payment experience (through current enquiry with SC's suppliers), our
delinquent payment and our debt collection record concerning SC.
Trade payment experience: SC did not provide any name of
trade/service suppliers and we have no other sources to conduct the enquiry at
present.
Delinquent payment record: None
in our database.
Debt collection record: No overdue amount owed by SC was placed to us for
collection within the last 6 years.
SC’s management declined to release its banking information.
Financial Summary
Unit: CNY’000
|
|
as
of Dec. 31, 2011 |
as
of Nov. 30, 2012 |
|
Total Liabilities |
785,412 |
1,097,426 |
|
Shareholders equities |
309,671 |
228,568 |
|
Total Assets |
1,095,083 |
1,325,994 |
|
|
|
|
|
|
as
of Dec. 31, 2011 |
Jan.
1 to Nov. 30, 2012 |
|
Turnover |
341,106 |
416,669 |
|
Operating profit |
-97,681 |
-81,623 |
|
Net profit |
-96,994 |
-81,103 |
Note: we did not
find SC’s detailed financial reports.
Important Ratios
|
|
as
of Dec. 31, 2011 |
as
of Nov. 30, 2012 |
|
*Liabilities to assets |
0.72 |
0.83 |
|
*Net profit margin (%) |
-28.44 |
-19.46 |
|
*Return on total assets (%) |
-8.86 |
-6.12 |
|
*Turnover/Total assets |
0.31 |
0.31 |
PROFITABILITY:
FAIR
·
The turnover of SC appears fairly good in its line.
·
SC’s net profit margin is poor.
·
SC’s return on total assets is fair.
·
SC’s turnover is in a fair level, comparing with
the size of its total assets.
LEVERAGE: FAIR
·
The debt ratio of SC is fairly high.
·
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fair.
SC is considered medium-sized in its line.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.98 |
|
|
1 |
Rs.101.49 |
|
Euro |
1 |
Rs.84.79 |
INFORMATION DETAILS
|
Report Prepared
by : |
NNA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to
overcome financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.